All AbMole products are for research use only, cannot be used for human consumption.
Foretinib is an oral multikinase inhibitor targeting Met, RON, Axl, and vascular endothelial growth factor receptor. Foretinib (XL880, GSK1363089) inhibits HGF receptor family tyrosine kinases with an IC50 of 3 nM for Ron. Foretinib (XL880, GSK1363089) also inhibits KDR, Flt-1, and Flt-4 with IC50 of 0.9, 6.8 and 2.8 nM, respectively. In addition, EXEL-2880 inhibits members of the platelet-derived growth factor receptor family and the angiopoietin-1 receptor Tie-2. Foretinib (XL880, GSK1363089) is the 1st orally available small molecule inhibitor of Met to enter the clinic and appears to be generally well tolerated.
Biomed Pharmacother. 2024 Jun 21.
The combination therapy using tyrosine kinase receptors inhibitors and repurposed drugs to target patient-derived glioblastoma stem cells
Foretinib purchased from AbMole
 |
Source | J Cancer (2017). Figure 2. Foretinib |
| Method | Apoptosis assay | |
| Cell Lines | ESCC cells | |
| Concentrations | 0.1 and 0.5 μM | |
| Incubation Time | 24h | |
| Results | The results demonstrated that foretinib significantly enhances apoptosis induced by ionizing radiation. |
 |
Source | J Cancer (2017). Figure 1. Foretinib |
| Method | Cell viability assay | |
| Cell Lines | ECA-109 and TE-13 cells | |
| Concentrations | 0.1 and 0.5 μM | |
| Incubation Time | 24h and 48h | |
| Results | Foretinib treatment (0.1 and 0.5 μM) combined ionizing radiation significantly shifted the dose-survival curves compared with the control group. |
| Cell Experiment | |
|---|---|
| Cell lines | B16F10 cells |
| Preparation method | HGF-induced migration assay. B16F10 cells (2 *105) were seeded onto 0.8 Am membranes in the top chamber of a 96-well Transwell plate in DMEM containing a serial dilution of EXEL-2880 and 0.1% FBS. DMEM containing HGF (50 ng/mL), 0.2% FBS, and EXEL-2880(foretinib) was added to the bottom chamber, and after 24 h, the medium was removed and Accutase (ISC BioExpress) was added to the bottom chamber. After 30 min, cells were transferred to a V-bottomed 96-well plate, centrifuged, and resuspended in HBSS containing 2 mg/mL calcein-AM (Molecular Probes). After incubation for 30 min, cells were transferred into a black 96-well plate. Fluorescence emission was measured at 480 nm using an excitation wavelength of 520 nm and imaged with a fluorescence microscope. |
| Concentrations | 14, 41, 123nM |
| Incubation time | 24h |
| Animal Experiment | |
|---|---|
| Animal models | ligand (e.g., HGF or VEGF)–induced receptor phosphorylation of Met in liver and Flk-1/KDR in lung |
| Formulation | 0.9% saline |
| Dosages | 100 mg/kg |
| Administration | oral gavage |
| Molecular Weight | 632.65 |
| Formula | C34H34F2N4O6 |
| CAS Number | 849217-64-7 |
| Solubility (25°C) | DMSO 90 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related c-Met Products |
|---|
| AMG-208
AMG-208 is a potent small molecular inhibitor c-Met with an IC50 of 9.3 nM. AMG-208 is also a CYP3A4 inhibitor with an IC50 of 32 μM. AMG-208 has anti-cancer activity. |
| BMS-777607
BMS-777607 is a selective and potent small-molecule met kinase inhibitor for c-Met, Axl, Ron and Tyro3 with IC50s of 3.9 nM, 1.1 nM, 1.8 nM and 4.3 nM, respectively. |
| BMS 794833
BMS-794833 is a potent ATP competitive Met/VEGFR-2 kinase inhibitor. |
| AMG-458
AMG-458 is a potent, selective and orally bioavailable c-Met inhibitor, with Ki values of 1.2 nM and 2.0 nM for human and mouse c-Met, respectively. |
| XL-184
Cabozantinib (XL184, BMS-907351) is a small molecule inhibits multiple receptor tyrosine kinases, specifically MET and VEGFR2 with IC50 values of 0.035 and 1.8 nM for VEGFR2 and Met respectively. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
